Trethera
  • Home
  • About Us
  • Technology
  • Pipeline
  • Media
    • News
    • Publications
  • Contact
  • Menu

News

Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy

19th April 2021/in News /by Trethera

Los Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies.  Trethera will […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-04-19 00:22:002021-05-26 00:59:43Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy

Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

16th March 2021/in News /by Trethera

Los Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-03-16 16:50:462021-03-16 16:52:33Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors

24th February 2021/in News /by Trethera

Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing.  Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-02-24 03:50:002021-03-08 18:05:11Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

7th January 2021/in News /by Trethera

Los Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2021-01-07 04:06:002021-03-08 17:55:55Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board

8th December 2020/in News /by Trethera

Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2020-12-08 04:17:002021-03-08 18:11:32Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board
Page 4 of 512345